Advances in the treatment of testicular cancer

Yaron Ehrlich; David Margel; Marc Alan Lubin; Jack Baniel

doi:10.3978/j.issn.2223-4683.2015.06.02

Advances in the treatment of testicular cancer

Yaron Ehrlich^*, David Margel, Marc Alan Lubin, Jack Baniel

^*Corresponding author for this work

Surgery

Rabin Medical Center Israel

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.

Original language	English
Pages (from-to)	381-390
Number of pages	10
Journal	Translational Andrology and Urology
Volume	4
Issue number	3
DOIs	https://doi.org/10.3978/j.issn.2223-4683.2015.06.02
State	Published - 2015

Keywords

Chemotherapy
Chemotherapy adjuvant
Lymph node excision
Neoplasm staging
Neoplasms germ cell tumor
Orchiectomy
Patient selection
Treatment outcome
incidence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3978/j.issn.2223-4683.2015.06.02

Cite this

@article{feef324af76946b38f12a67056bd53aa,

title = "Advances in the treatment of testicular cancer",

abstract = "Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.",

keywords = "Chemotherapy, Chemotherapy adjuvant, Lymph node excision, Neoplasm staging, Neoplasms germ cell tumor, Orchiectomy, Patient selection, Treatment outcome, incidence",

author = "Yaron Ehrlich and David Margel and Lubin, {Marc Alan} and Jack Baniel",

note = "Publisher Copyright: {\textcopyright} Translational Andrology and Urology.",

year = "2015",

doi = "10.3978/j.issn.2223-4683.2015.06.02",

language = "אנגלית",

volume = "4",

pages = "381--390",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

number = "3",

}

TY - JOUR

T1 - Advances in the treatment of testicular cancer

AU - Ehrlich, Yaron

AU - Margel, David

AU - Lubin, Marc Alan

AU - Baniel, Jack

N1 - Publisher Copyright: © Translational Andrology and Urology.

PY - 2015

Y1 - 2015

N2 - Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.

AB - Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.

KW - Chemotherapy

KW - Chemotherapy adjuvant

KW - Lymph node excision

KW - Neoplasm staging

KW - Neoplasms germ cell tumor

KW - Orchiectomy

KW - Patient selection

KW - Treatment outcome

KW - incidence

UR - http://www.scopus.com/inward/record.url?scp=84934280962&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2223-4683.2015.06.02

DO - 10.3978/j.issn.2223-4683.2015.06.02

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:84934280962

SN - 2223-4683

VL - 4

SP - 381

EP - 390

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

IS - 3

ER -

Advances in the treatment of testicular cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this